2021-01-11,Enlivex to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
2020-12-31,Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
2020-12-21,Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv
2020-12-09,"Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News"
2020-12-07,Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy
2020-12-03,"Why Sutro, Lumos And More Health Care Stocks Are Moving Today"
2020-12-03,Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
2020-11-18,Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra
2020-11-17,"Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Companys Board of Directors"
2020-11-11,"Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwrights 6th Annual Israel Conference"
2020-11-05,"Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohns Disease, and Ulcerative Colitis with Allocetra Immunotherapy"
2020-11-03,What's in the Cards for Enlivex (ENLV) This Earnings Season?
2020-11-03,Enlivex: Israeli Ministry of Health Authorizes Initiation of Phase IIb Clinical Trial Evaluating Safety and Efficacy of Allocetra in Sepsis Patients
2020-10-27,"Enlivex to Host COVID-19 Webinar: The Staging of a New Disease and Its Implications for Treatment Options, with Mount Sinai Key Opinion Leader"
2020-10-22,Enlivex Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
2020-10-13,"Enlivex: After Expedited Review, Israeli Ministry of Health Authorizes Initiation of Phase II Clinical Trial Evaluating Allocetra in COVID-19 Severe and Critical Patients"
2020-10-02,What You Need To Know About Enlivex Therapeutics Ltd.'s (NASDAQ:ENLV) Investor Composition
2020-10-01,"Bed Bath & Beyond, Enlivex: 5 Top Stock Gainers for Thursday"
2020-10-01,Enlivex Pharmaceutical Shares Surge After Positive COVID-19 Treatment Data
2020-10-01,"The Daily Biotech Pulse: Amag Spikes On Takeover Rumors, Zosano Wilts On Regulatory Setback, Pulmonx Makes Wall Street Debut"
2020-10-01,Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
2020-09-16,Enlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy
2020-08-25,Enlivex Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy
2020-08-10,Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure
2020-07-20,"Enlivex Announces a new publication Apoptotic cell therapy for cytokine storm associated with acute severe sepsis in Cell Death & Disease, a Nature Research Journal"
2020-06-18,Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy
2020-06-01,Enlivex Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
2020-05-28,Enlivex Presents New Clinical Data Demonstrating Early Resolution of Cytokine Storms in Sepsis Patients Treated with Allocetra at the International Society for Cellular Therapy 2020 Paris Virtual Annual Meeting
2020-05-20,We're Not Very Worried About Enlivex Therapeutics's (NASDAQ:ENLV) Cash Burn Rate
2020-05-07,Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients
2020-04-13,Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials
2020-03-18,Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis
2020-03-09,Israel Patent Office Grants New Patent Covering Enlivexs Allocetra Immunotherapy Treatment
2020-03-05,Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering
2020-03-03,Enlivex Therapeutics Confirms Public Statements Made by the Head of Israel Economic and Commercial Mission to South Korea
2020-03-02,Enlivex Therapeutics Announces $16.75 Million Registered Direct Offering
2020-02-26,Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering
2020-02-25,18 Medical Stocks To Watch Amid The Coronavirus Outbreak
2020-02-24,Enlivex Therapeutics Announces $8.0 Million Registered Direct Offering
2020-02-24,Enlivex's stock rockets after plans to boost in capacity for treatment of COVID-19-like symptoms
2020-02-24,Enlivex Therapeutics Announces Plan for Increased Production Capacity of AllocetraTM in Preparation for Potential Treatment of Coronavirus (COVID-19) Patients with Organ Failure
2020-02-20,"Data On Enlivexs Allocetra-OTS Immunotherapy for Peritoneal Solid Tumors and for Prevention of GvHD Selected for Presentation at the Transplantation & Cellular Therapy Meetings Conference (TCT) in Orlando, Florida"
2019-11-21,Enlivex Therapeutics Ltd. Announces Withdrawal of Proposed Offering of Ordinary Shares
2019-11-20,Enlivex Therapeutics Ltd. Announces Proposed Offering of Ordinary Shares
2019-11-18,Enlivex Therapeutics Completes Recruitment In Phase Ib Trial Evaluating Safety And Efficacy Of Universal Off-The-Shelf Allocetra In Patients With Severe Sepsis
2019-11-12,Enlivex Therapeutics To Present At The 10th Annual Jefferies 2019 London Healthcare Conference
2019-11-05,"Company News For Nov 5, 2019"
2019-11-04,Enlivex Therapeutics Announces Positive Interim Safety and Efficacy Data From Ongoing Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis
2019-10-30,Enlivex Therapeutics (NASDAQ:ENLV) Is In A Good Position To Deliver On Growth Plans
2019-10-24,Enlivex Announces Appointment of New Chief Executive Officer
2019-10-10,Preclinical Data Indicating Allocetra-OTS As Potential Therapy For Prevention Of Organ Failure And Mortality Associated with Severe Sepsis Selected For Presentation At The XVIIIth Congress Of the European and Int'l Shock Societies
2019-10-08,European Patent Office Grants New Patent Covering Enlivexs Allocetra Immunotherapy Treatment
2019-10-07,Data On Combination Of Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Selected For Presentation At The European Molecular Biology Organizations 2019 Cell Death in Immunity and Inflammation Workshop
2019-09-23,First Data On Combination Of Enlivexs Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Revealed At The Joint IIS-ISCR Special 2019 Conference
2019-09-09,New Patent Covering Enlivexs AllocetraTM Immunotherapy Was Allowed By The Israeli Patent Authority
2019-09-04,"Enlivex Therapeutics To Present At The 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co."
2019-08-19,Enlivex Therapeutics Announces Positive Outcome From Safety Committees Review Of Six Patients With Severe Sepsis Patients; Enrollment Of Last Study Cohort Approved
2019-08-01,Can We See Significant Insider Ownership On The Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Share Register?
2019-07-16,Immunotherapy Company Enlivex Announces Dual Listing on the Tel-Aviv Stock Exchange
2019-06-18,Australian Patent Office Grants New Patent Covering Enlivexs AllocetraTM Immunotherapy Treatment
2019-06-06,Enlivex Therapeutics Provides Clinical Update on Positive Safety Profile of Its Off-The-Shelf Cell Therapy Product in First Three Severe Sepsis Patients
2019-05-30,Enlivex Therapeutics to Present at The 2019 Jefferies Global Healthcare Conference
2019-04-18,IMMUNOTHERAPY COMPANY ENLIVEX THERAPEUTICS SELECTED TO RECEIVE AN ADDITIONAL $1 MILLION GRANT BY THE ISRAEL INNOVATION AUTHORITY FOR ITS SEPSIS CLINICAL PROGRAM
2019-04-08,"IMMUNOTHERAPY COMPANY ENLIVEX THERAPEUTICS COMPLETES PREVIOUSLY ANNOUNCED FINANCING PRICED AT $12.25 PER SHARE, RAISING A TOTAL OF APPROXIMATELY $8.4 MILLION"
2019-04-04,ENLIVEX THERAPEUTICS TO PRESENT AT THE 2019 H.C. WAINWRIGHT GLOBAL LIFE SCIENCES CONFERENCE
2019-03-26,Immunotherapy Company Enlivex Therapeutics Announces Nasdaq Listing Under Symbol ENLV and Closing of Private Placement of Ordinary Shares Priced at $12.25 Per Share
